U.S. Specialty Stores Stock News

ProFrac Holding Corp. recently reported its Q4 and full-year 2025 results, showing profitability that exceeded expectations despite a softer North American completions market and announcing a cost optimization plan targeting US$100 million in annualized savings by mid-2026. This combination of resilient profitability and an aggressive efficiency program highlights how ProFrac’s vertically integrated model can support margins even when industry activity weakens. We’ll now examine how the new...

In March 2026, Lockheed Martin and the Department of War announced a framework agreement to accelerate and ultimately quadruple production capacity for Precision Strike Missiles, building on a prior US$4.94 billion U.S. Army contract and enabling potential multi-year deals of up to seven years pending future congressional approval. The framework not only expands advanced missile output but also signals a deeper, longer-term production commitment that could reshape Lockheed Martin’s...

Insulet Corporation recently appointed Mike Panos as Executive Vice President and Chief Commercial Officer, placing him in charge of the company’s global commercial organization under President and CEO Ashley McEvoy and adding him to the Executive Leadership Team. Panos’ three decades of medical technology commercial leadership at Stryker, including responsibility for large global businesses, suggests Insulet is prioritizing disciplined commercial execution and talent development as it seeks...

Bausch + Lomb recently reported positive 24‑month results from its pivotal U.S. trial of the implant‑free ELIOS excimer laser system for treating mild to moderate open‑angle glaucoma during cataract surgery, showing meaningful intraocular pressure reduction and a safety profile comparable to cataract surgery alone. The strong proportion of patients achieving at least a 20% drop in unmedicated intraocular pressure and remaining medication‑free for nearly two years highlights how ELIOS could...

On 23 March 2026, Dimensional Fund Advisors announced it had appointed State Street as end-to-end service provider for its first-of-its-kind U.S. ETF share class structure under new SEC exemptive relief, while State Street also added former top U.S. intelligence official Susan Gordon to its Board. This combination of pioneering ETF servicing work and enhanced board-level expertise in technology, cybersecurity and geopolitical risk could strengthen State Street’s role as a global...

On March 26, 2026, Archer-Daniels-Midland filed a definitive proxy statement urging shareholders to vote against a pesticide-use reporting proposal tied to its regenerative agriculture disclosures, while the EPA recently raised required biofuel blending levels in gasoline and diesel, supporting demand for crop-based feedstocks. This combination of increased regulatory support for biofuels and investor pressure on pesticide transparency highlights how policy and shareholder scrutiny are...

Old Second Bancorp overview and recent share performance Old Second Bancorp (OSBC) has drawn investor attention after recent share price moves, with the stock closing at $19.57. Returns are mixed, with a 0.7% decline over the past week and modest month performance. See our latest analysis for Old Second Bancorp. Recent trading has been relatively muted, with slight share price softness over the past month but a stronger 1 year total shareholder return of 19.34%, indicating that longer term...

In recent months, Janus Henderson’s Forty Fund highlighted Madrigal Pharmaceuticals’ success with Rezdiffra, the first FDA-approved MASH therapy, while the company also signed a global licensing deal with Suzhou Ribo Life Science and Ribocure for six preclinical siRNA programs targeting metabolic liver disease. Together, strong early Rezdiffra adoption and an expanded siRNA pipeline suggest Madrigal is moving from a single-product story toward a broader MASH-focused franchise. Next, we’ll...

Earlier this month, Vaxcyte announced it had fully enrolled its OPUS-1 and OPUS-2 Phase 3 trials of VAX-31, a 31-valent pneumococcal conjugate vaccine for adults, and recently published positive Phase 1/2 VAX-31 data in The Lancet Infectious Diseases. These milestones, together with FDA-aligned Phase 3 designs intended to support a future Biologics License Application, underscore VAX-31’s potential to broaden pneumococcal disease coverage versus existing adult vaccines. We’ll now examine how...

Why Dauch (DCH) is on investors' radar today Dauch (DCH) has drawn attention after its recent rebrand from American Axle & Manufacturing Holdings, Inc., a shift that spotlights its role in driveline and metal forming technologies across electric, hybrid, and internal combustion vehicles. See our latest analysis for Dauch. Despite the recent name change, the short term picture has been softer, with a 30 day share price return of 15% and a year to date share price return of 13.6%, while the 1...

Corebridge Financial stock: recent performance snapshot Corebridge Financial (CRBG) has drawn attention after recent share price weakness, with the stock showing negative returns over the past month, past 3 months and year to date, prompting investors to reassess its risk and return trade off. See our latest analysis for Corebridge Financial. At a share price of US$22.30, Corebridge Financial has seen momentum fade recently, with a 30 day share price return of 13.70% decline and a 1 year...

Blackstone (BX) has committed US$250 million to Advanced Digital Gaming Technology, a new Abu Dhabi based payments and data intelligence platform, putting regulated digital and gaming payments in the Middle East and Africa in sharper investor focus. See our latest analysis for Blackstone. Despite the ADGT announcement putting digital payments in focus, Blackstone’s recent price action has been weak. A 30 day share price return of 4.67% and a 90 day share price return of 30.18% have...

Event context and recent share performance First Interstate BancSystem (FIBK) has recently traded around $32.81, with the stock showing a 2.1% decline over the past day and a 5.2% decline over the past month, while year to date performance is a 7.1% decline. Over the past 3 months, the stock shows a 6.7% decline, but the 1 year total return stands at 21.7% and the 3 year total return at 35.6%, compared with a 6.3% decline over 5 years. See our latest analysis for First Interstate...

Wondering whether Woodward at around US$351 per share still offers value, or if most of the upside is already reflected in the price? This article breaks down what the current market price might be implying about the company. The stock has been volatile recently, with a 2.9% decline over the last 7 days and a 9.2% decline over the last 30 days, even though the year to date return is 13.0% and the 1 year return is 93.3%. Over a longer stretch, Woodward has returned 262.8% over 3 years and...

Why Macy's AI push matters for stock watchers Macy's (M) is drawing fresh attention after reporting early results from its new AI shopping tools, with test customers spending about 4.75 times more than those who did not use the assistant. This shift toward AI driven recommendations and virtual try ons sits alongside recent earnings, guidance and buybacks, giving investors new context for thinking about how the retailer is trying to influence customer behavior and support engagement. See our...

Wondering whether Establishment Labs Holdings is attractively priced today, or whether the recent share price leaves limited value on the table? This article breaks down what the current valuation figures actually say. The stock trades at US$55.31, with a 1 year return of 35.5% but a 30 day decline of 29.7% and a 7 day decline of 7.2%, so recent moves may have shifted how the market is pricing risk and opportunity. Over longer periods, returns of a 23.0% decline over 3 years and an 18.0%...

Are you wondering whether Intuit at around US$416 per share still makes sense for your portfolio, or if the recent price leaves too little potential upside? The stock has seen a 1.8% return over the past 30 days, compared with a much steeper 8.9% decline over the last week and a 31.7% drop over the past year. These moves can influence how the market views both its potential and its risks. Recent attention on Intuit has focused on its position as a core software provider to individuals and...

Why Horace Mann Educators (HMN) is on investors’ radar Horace Mann Educators (HMN) has drawn fresh attention after a period of mixed share performance, including a 1.3% decline over the past day and an 8.9% decline over the past 3 months. For investors following insurance names, the stock’s recent moves sit against a backdrop of US$1.7b in annual revenue and US$162.1m in net income across its three core segments. See our latest analysis for Horace Mann Educators. Across a longer window, HMN’s...

The US Federal Trade Commission has issued formal warnings to Mastercard and other major payment networks about debanking practices. The warning focuses on compliance with requirements around viewpoint neutrality and access to financial services. The communication signals potential regulatory follow up and enforcement risk tied to how accounts and transactions are handled. For Mastercard (NYSE:MA), this regulatory attention arrives at a time when the stock is trading at $484.24, with the...

Doximity recently highlighted that its platform now reaches over 80% of U.S. physicians and has delivered annual revenue growth of about 29.3% over the past five years, while generating strong free cash flow that can be used for investment or capital returns. This combination of broad physician adoption and substantial cash generation underscores Doximity’s position as a core digital tool for clinicians and a financially flexible business within healthcare technology. Next, we’ll examine how...

Recent Stock Performance and Business Context Travere Therapeutics (TVTX) has drawn investor attention after recent trading that leaves the shares about 8.5% lower over the past month and roughly 27.7% lower over the past 3 months. The company focuses on therapies for rare kidney and metabolic diseases, generates US$490.7m in revenue, and currently reports a net loss of US$50.3m, which keeps profitability and funding on many investors’ radar. See our latest analysis for Travere...

ServiceNow (NYSE:NOW) announced a record $7.75b acquisition of cybersecurity firm Armis, expanding its AI powered platform deeper into security. The deal marks the largest acquisition in ServiceNow's history and follows recent alliances focused on AI agent resilience and security, including partnerships with Cohesity and Zenity. This move raises fresh questions around capital allocation, risk management, and how security will sit alongside ServiceNow's core workflow and automation...

United Therapeutics reported positive phase 3 results from its TETON-1 study of nebulized Tyvaso in idiopathic pulmonary fibrosis (IPF). The trial met its primary efficacy endpoint and showed significant benefits over placebo with a favorable safety profile. The company plans to seek a supplemental FDA approval to add IPF to the Tyvaso label, supported by integrated data from TETON-1 and TETON-2. For investors watching United Therapeutics, ticker NasdaqGS:UTHR, this news arrives with the...

If you are wondering whether Franklin Resources at around US$22.75 is offering good value or potential overpayment, the recent share price path gives you a useful starting point. The stock has seen a 4.8% decline over the last week and a 14.3% decline over the last month, yet it still shows a 23.1% return over the past year, which can change how investors think about both risk and opportunity. Across the market, investors have been closely watching asset managers as sentiment around capital...